v3.24.1.u1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Feb. 29, 2024
Feb. 28, 2023
Feb. 29, 2024
Feb. 28, 2023
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)        
Revenue $ 145,000 $ 20,025 $ 296,278 $ 117,760
Cost of goods sold 0 2,958 4,822 18,753
Gross profit 145,000 17,067 291,456 99,007
Operating expenses        
Research and development 245,779 696,178 820,270 1,525,667
General and administrative 567,226 644,514 1,278,333 1,592,384
Total operating expenses 813,005 1,340,692 2,098,603 3,118,051
Loss from operations (668,005) (1,323,625) (1,807,147) (3,019,044)
Other income (loss)        
Interest income (expense) (1) 14,990 7,318 18,731
Unrealized gain (loss) on marketable securities 15,273 (2,003) (37,942) (79,631)
Total other income (loss) 15,272 12,987 (30,624) (60,900)
Net loss (652,733) (1,310,638) (1,837,771) (3,079,944)
Less: Net loss attributable to non-controlling interest (3,194) (12,507) (8,909) (25,869)
Net loss attributable to Lexaria shareholders (649,539) (1,298,131) (1,828,862) (3,054,075)
Other comprehensive loss        
Foreign currency translation adjustment (24,998) 0 (20,626) 0
Total comprehensive loss $ (674,537) $ (1,298,131) $ (1,849,488) $ (3,054,075)
Basic and diluted loss per share $ (0.06) $ (0.22) $ (0.18) $ (0.52)
Weighted average number of common shares outstanding        
- Basic and diluted 10,765,143 5,950,998 9,970,489 5,950,998

Source